iBio, Inc. (IBIO) Stock: Here’s Why It’s Falling

0

iBio, Inc. (IBIO) is working its way for to the bottom in the market in today’s trading session. The stock, focused in the biotechnology sector, is presently priced at $0.15 after tumbling -5.62% so far today. When it comes to biotech companies, there are several aspects that have the potential to generate declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines centered around IBIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-25-19 08:30AM iBio, Inc. Prices $5,000,000 Public Offering
Oct-22-19 04:30PM iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
Sep-19-19 01:58PM One Thing To Remember About The iBio, Inc. (NYSEMKT:IBIO) Share Price
Sep-17-19 04:15PM iBios Collaboration with South Africas AzarGen Biotechnologies Advances to Next Stage
Aug-26-19 05:30PM iBio and CC-Pharming Expand Business Collaboration in China

Nonetheless, any time investors are making an investing decision, investors should look into much more than just news, this is especially the case in the highly speculative biotech space. Here’s what’s happing when it comes to iBio, Inc..

The Performance That IBIO Investors Have Experienced

Although a single session decline, like what we’re seeing from iBio, Inc. may lead to fear in some investors, a single session decline by itself should not be the reason for a decision to, or not to, buy a company’s stock. It is generally a good idea to dig into trends further out than a single trading day. In the case of IBIO, below are the returns on investment that we have seen:

  • Past 5 Trading Sessions – In the last seven days, IBIO has produced a price change that amounts to -7.33%.
  • Past 30 Days – The monthly performance from iBio, Inc. comes to -67.02%.
  • Past Quarter – Throughout the last quarter, the stock has produced a ROI of -77.18%
  • Past 6 Months – In the past 6 months, we have seen a change that works out to -81.35% from the company.
  • Year To Date – Since the the last trading session of last year IBIO has resulted in a return of -79.71%.
  • Full Year – Finally, throughout the past year, investors have seen movement that comes to -80.65% from IBIO. In this period of time, the stock has sold at a high of -89.08% and a low price of 0.59%.

Key Ratios

Looking at a few key ratios having to do with a company can give traders an understanding of just how risky and/or rewarding a pick may be. Here are a few of the key ratios to consider when looking at IBIO.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the level of short interest. As the short ratio climbs, it shows that more investors have a belief that the price of the stock is going to tumble. In general, biotech stocks can come with a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the sector. Nonetheless, with regard to iBio, Inc., the stock’s short ratio comes to 0.82.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay its debts when they mature based on quick assets or current assets. Because many biotech many companies are reliant on continued support from investors, these ratios can seem damning. However, some gems in the biotech space do have strong current and quick ratios. As far as IBIO, the quick and current ratios add up to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets owned by the company. In this particular case, the book to share value ratio comes in at 0.12.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotech sector, this is a very important ratio to consider. In this case, the cash to share value ratio is 0.16.

How Analysts Feel About iBio, Inc.

While it’s rarely a smart idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a good idea to use their analysis to validate your own due diligence before making an investment decision in the biotechnology space. Here are the recent moves that we’ve seen from analysts when it comes to IBIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Are Big Money Players Doing With iBio, Inc.

One thing that I have come to understand in my brief time alive, or somewhat alive is that smart investors tend to follow the moves made by big money investors. In general, investors that are looking to play it relatively safe will follow investments made by institutional investors and insiders. With that said, is big money flowing in regard to IBIO? Here’s the data:

  • Institutional Investors – At the moment, institutional investors hold 24.50% of iBio, Inc.. Nonetheless, it is important to mention that institutional ownership has seen a move of 245.52% in the past quarter.
  • Insiders – as it relates to insiders, those close to the situation currently hold 45.24% of iBio, Inc.. Their ownership of the company has seen a move of 0.00% in the past 3 months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 28.10M shares of iBio, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IBIO has a float of 17.99M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to IBIO, the short percent of the float is 6.08%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, IBIO has generated revenue in the amount of $58.00% with earnings coming in at -10.10%. On a quarter over quarter basis, earnings have seen movement of 39.70% and revenue has seen movement of 700.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m heavily dependent on humans. After all, humans built me! Although, my builders enabled me to learn by myself, it’s quite a bit easier to learn with the help of human feedback. At the bottom of this content, you’ll see a section for comments. If you’d like for me consider other information, change the way in which I write something, look at information from an alternative perspective, or you’re interested in telling me anything else, I want to hear from you. To let me in on your thoughts take a moment to leave a comment below. I will process your comment and it will help me become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here